MedElevator Войти в исследования
← Поиск публикаций

DOI 10.2174/0118715206350342241224073809

Медицинская библиотека · Anti-cancer agents in medicinal chemistry · 2025

A Systematic Review and Meta-analysis on the Safety and Efficacy of CAR T Cell Therapy Targeting GPRC5D in Patients with Multiple Myeloma: A New Insight in Cancer Immunotherapy.

Robat-Jazi Behrouz, Mahalleh Mehrdad, Dashti Mohsen, Nejati Negar, Ahmadpour Mahsa, Alinejad Erfan, Mohammadi Shiva, Lorestani Parsa, Hamidieh Amir Ali, Habibi Mohammad Amin, Jadidi-Niaragh Farhad

СтатьяСистематический обзорМетаанализПеревод пока не подготовлен

Аннотация

BACKGROUND

Despite ongoing advances and introducing innovative therapeutic approaches for the treatment of multiple myeloma (MM), relapses are common, with low overall survival rates. G protein-coupled receptor, class C, group 5, and member D (GPRC5D) has been expressed in several myeloma cell lines and has demonstrated encouraging outcomes results in in-vitro studies as a potential target for immunotherapies.

OBJECTIVE

We aimed to investigate the safety and efficacy of GPRC5D-targeted CAR T cell therapies in MM patients.

METHODS

On August 24, 2023, the databases of PubMed, Scopus, Embase, and Web of Science were systematically searched for pertinent studies. After completing a two-step title/abstract and full-text screening process, the eligible studies were included.

RESULTS

Following the screening of 107 articles, four studies of 130 multiple myeloma patients treated with GPRC5D-targeted CAR T-cell therapy were included. The meta-analyses showed an ORR of 87% (95% CI [81- 93%]), with 74% (95% CI [65-73%]) for those with prior BCMA-targeted therapy and 88% (95% CI [78-99%]) for those without. PR was 25%, VGPR 33%, and CR/sCR 48%, with 65% achieving MRD-negativity. In terms of safety, hematologic AEs were common, with anemia reported in 86% of patients. Non-hematologic common AEs included CRS (83%, 5% grade ≥3) and hypocalcemia (63%, 10% grade ≥3). No significant publication bias was detected.

CONCLUSION

GPRC5D is an active and safe target that shows promising results in the treatment of relapsed and/or refractory (R/R) MM and heavily pretreated patients.

Для цитирования: Robat-Jazi Behrouz, Mahalleh Mehrdad, Dashti Mohsen, Nejati Negar, Ahmadpour Mahsa, Alinejad Erfan, Mohammadi Shiva, Lorestani Parsa, Hamidieh Amir Ali, Habibi Mohammad Amin, Jadidi-Niaragh Farhad. A Systematic Review and Meta-analysis on the Safety and Efficacy of CAR T Cell Therapy Targeting GPRC5D in Patients with Multiple Myeloma: A New Insight in Cancer Immunotherapy.. Anti-cancer agents in medicinal chemistry. 2025. DOI: 10.2174/0118715206350342241224073809.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.